-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The National Joint Procurement Office of Proprietary Chinese Medicines was established, which for the first time collected 16 kinds of drugs and involved more than 10 billion markets, and this collection was led by Hubei, with a total of 29 provinces and cities participating, and Fujian and Hunan did not participate
.
.
Recently, under the guidance of the National Medical Insurance Bureau, the Hubei Provincial Medical Security Bureau issued an invitation to all provinces across the country to take the lead in establishing the National Joint Procurement Office of Proprietary Chinese Medicines and establishing a procurement mechanism
for the National Alliance of Proprietary Chinese Medicines after the collection of the Interprovincial Alliance of Proprietary Chinese Medicines in 19 Provinces in 2021.
for the National Alliance of Proprietary Chinese Medicines after the collection of the Interprovincial Alliance of Proprietary Chinese Medicines in 19 Provinces in 2021.
In the second half of 2021, Hubei led 19 provinces (autonomous regions and municipalities) to form an inter-provincial alliance of proprietary Chinese medicines and carried out a six-month collection of proprietary Chinese medicines
.
182 products of 157 enterprises participated in the quotation, the procurement scale was nearly 10 billion yuan, 97 enterprises, 111 products were selected, the selection rate reached 62%, the average price of the selection was 42.
27%, the maximum reduction was 82.
63%, and it is expected to save more than 3 billion yuan
in drug costs every year.
.
182 products of 157 enterprises participated in the quotation, the procurement scale was nearly 10 billion yuan, 97 enterprises, 111 products were selected, the selection rate reached 62%, the average price of the selection was 42.
27%, the maximum reduction was 82.
63%, and it is expected to save more than 3 billion yuan
in drug costs every year.
By combining five major innovations, such as generic name procurement, comprehensive scoring shortlisting, combination of intra-product competition and inter-product competition to break the bid-rigging, introducing medical institution recognition indicators, and the lowest daily average treatment cost can be selected, the collection system solved the difficulties
of collection and collection such as the difficulty of evaluating the quality of proprietary Chinese medicines and the unique products of proprietary Chinese medicines.
of collection and collection such as the difficulty of evaluating the quality of proprietary Chinese medicines and the unique products of proprietary Chinese medicines.
Overall, the results of the selected price have reached expectations, which is generally in line with the principle of volume-price linkage, and the vast majority of products, especially those with large purchases, have reached a considerable decline
.
.
The ice-breaking move of Hubei proprietary Chinese medicine collection and mining has broken the concept of "proprietary Chinese medicine is a forbidden area for collection and procurement" in the industry, marking the expansion of the centralized procurement reform to the field of proprietary Chinese medicine, which is of great significance
for the all-round promotion of the centralized procurement reform.
Its social recognition is high, the breakthrough progress is large, and the collection process and results have been fully affirmed
by the leaders of the State Bureau and the majority of peers in the industry.
for the all-round promotion of the centralized procurement reform.
Its social recognition is high, the breakthrough progress is large, and the collection process and results have been fully affirmed
by the leaders of the State Bureau and the majority of peers in the industry.
In this context, the National Medical Insurance Bureau asked Hubei to once again carry out the collection and procurement of the Chinese Patent Medicine Alliance, which fully demonstrated the trust and trust
of the National Medical Insurance Bureau in Hubei's medical insurance work.
On the basis of the first batch of 19 inter-provincial alliances, Hubei has invited all provinces in the country to establish a procurement mechanism
for the National Alliance of Proprietary Chinese Medicines.
Following the Shanghai National Alliance for Chemical and Biological Drugs and the Tianjin Consumables National Collection and Collection Alliance, Hubei is expected to become a national center for the collection and collection of
proprietary Chinese medicines.
of the National Medical Insurance Bureau in Hubei's medical insurance work.
On the basis of the first batch of 19 inter-provincial alliances, Hubei has invited all provinces in the country to establish a procurement mechanism
for the National Alliance of Proprietary Chinese Medicines.
Following the Shanghai National Alliance for Chemical and Biological Drugs and the Tianjin Consumables National Collection and Collection Alliance, Hubei is expected to become a national center for the collection and collection of
proprietary Chinese medicines.
It is reported that the National Alliance for the Collection and Collection of Proprietary Chinese Medicines has continued the concept of the first batch of proprietary Chinese medicines, and in accordance with the principle of "large clinical use and high procurement amount", 16 procurement groups containing 42 drugs have been formed, and the estimated market amount involved is more than 10 billion yuan
.
.
In view of the difficulty in evaluating the quality of proprietary Chinese medicines, the characteristics of many exclusive products, high market concentration, and the large differences in the price and decline of different selected products in individual product groups that appear in the first batch of collections, how the collection will continue to optimize and improve from the level of rules requires the entire proprietary Chinese medicine industry to wait and see
.
.
The National Joint Procurement Office of Proprietary Chinese Medicines was established, which for the first time collected 16 kinds of drugs and involved more than 10 billion markets, and this collection was led by Hubei, with a total of 29 provinces and cities participating, and Fujian and Hunan did not participate
.
.
Recently, under the guidance of the National Medical Insurance Bureau, the Hubei Provincial Medical Security Bureau issued an invitation to all provinces across the country to take the lead in establishing the National Joint Procurement Office of Proprietary Chinese Medicines and establishing a procurement mechanism
for the National Alliance of Proprietary Chinese Medicines after the collection of the Interprovincial Alliance of Proprietary Chinese Medicines in 19 Provinces in 2021.
for the National Alliance of Proprietary Chinese Medicines after the collection of the Interprovincial Alliance of Proprietary Chinese Medicines in 19 Provinces in 2021.
In the second half of 2021, Hubei led 19 provinces (autonomous regions and municipalities) to form an inter-provincial alliance of proprietary Chinese medicines and carried out a six-month collection of proprietary Chinese medicines
.
182 products of 157 enterprises participated in the quotation, the procurement scale was nearly 10 billion yuan, 97 enterprises, 111 products were selected, the selection rate reached 62%, the average price of the selection was 42.
27%, the maximum reduction was 82.
63%, and it is expected to save more than 3 billion yuan
in drug costs every year.
Enterprise procurement procurement.
182 products of 157 enterprises participated in the quotation, the procurement scale was nearly 10 billion yuan, 97 enterprises, 111 products were selected, the selection rate reached 62%, the average price of the selection was 42.
27%, the maximum reduction was 82.
63%, and it is expected to save more than 3 billion yuan
in drug costs every year.
By combining five major innovations, such as generic name procurement, comprehensive scoring shortlisting, combination of intra-product competition and inter-product competition to break the bid-rigging, introducing medical institution recognition indicators, and the lowest daily average treatment cost can be selected, the collection system solved the difficulties
of collection and collection such as the difficulty of evaluating the quality of proprietary Chinese medicines and the unique products of proprietary Chinese medicines.
of collection and collection such as the difficulty of evaluating the quality of proprietary Chinese medicines and the unique products of proprietary Chinese medicines.
Overall, the results of the selected price have reached expectations, which is generally in line with the principle of volume-price linkage, and the vast majority of products, especially those with large purchases, have reached a considerable decline
.
.
The ice-breaking move of Hubei proprietary Chinese medicine collection and mining has broken the concept of "proprietary Chinese medicine is a forbidden area for collection and procurement" in the industry, marking the expansion of the centralized procurement reform to the field of proprietary Chinese medicine, which is of great significance
for the all-round promotion of the centralized procurement reform.
Its social recognition is high, the breakthrough progress is large, and the collection process and results have been fully affirmed
by the leaders of the State Bureau and the majority of peers in the industry.
for the all-round promotion of the centralized procurement reform.
Its social recognition is high, the breakthrough progress is large, and the collection process and results have been fully affirmed
by the leaders of the State Bureau and the majority of peers in the industry.
In this context, the National Medical Insurance Bureau asked Hubei to once again carry out the collection and procurement of the Chinese Patent Medicine Alliance, which fully demonstrated the trust and trust
of the National Medical Insurance Bureau in Hubei's medical insurance work.
On the basis of the first batch of 19 inter-provincial alliances, Hubei has invited all provinces in the country to establish a procurement mechanism
for the National Alliance of Proprietary Chinese Medicines.
Following the Shanghai National Alliance for Chemical and Biological Drugs and the Tianjin Consumables National Collection and Collection Alliance, Hubei is expected to become a national center for the collection and collection of
proprietary Chinese medicines.
of the National Medical Insurance Bureau in Hubei's medical insurance work.
On the basis of the first batch of 19 inter-provincial alliances, Hubei has invited all provinces in the country to establish a procurement mechanism
for the National Alliance of Proprietary Chinese Medicines.
Following the Shanghai National Alliance for Chemical and Biological Drugs and the Tianjin Consumables National Collection and Collection Alliance, Hubei is expected to become a national center for the collection and collection of
proprietary Chinese medicines.
It is reported that the National Alliance for the Collection and Collection of Proprietary Chinese Medicines has continued the concept of the first batch of proprietary Chinese medicines, and in accordance with the principle of "large clinical use and high procurement amount", 16 procurement groups containing 42 drugs have been formed, and the estimated market amount involved is more than 10 billion yuan
.
Pharmaceuticals.
In view of the difficulty in evaluating the quality of proprietary Chinese medicines, the characteristics of many exclusive products, high market concentration, and the large differences in the price and decline of different selected products in individual product groups that appear in the first batch of collections, how the collection will continue to optimize and improve from the level of rules requires the entire proprietary Chinese medicine industry to wait and see
.
.
